After Spate of Transformative Acquisitions, Endo Reports Robust Growth for 1H 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
Endo's blended business model appears to be paying off in the near term as the company raises guidance for 2011, driven by the acquisition of American Medical Systems in June and strength in its core franchises.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011
During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
Medical Device and In Vitro Diagnostics/Research Deals Statistics Quarterly, Q2 2011
During the second quarter of 2011, 57 medical device companies brought in a total of $1.7 billion in financings. The M&A activity reached $28.8 billion, unusually high due to Johnson & Johnson's $21.7 billion takeover of orthopedic device maker Synthes. VC funding represented $76 million or 43% of the second quarter's in vitro diagnostics/research financing aggregate of $177 million. A hefty $4.1 billion was spent on 11 in vitro diagnostic/research M&A transactions, the largest being Thermo Fisher's $3.5 billion buy of Swedish genetics testing firm Phadia AB.
Endo Dives Deeper Into Devices With AMS Acquisition
With the $2.9 billion acquisition of American Medical Systems, Endo is further diversifying its specialty pharma portfolio into devices and services.